Magenta Therapeutics Analyst Ratings
Magenta Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/26/2023 | — | Wedbush | Downgrades | Outperform → Neutral | |
| 12/21/2022 | 506.06% | BTIG | $6 → $3 | Maintains | Buy |
| 08/25/2022 | 304.04% | Goldman Sachs | → $2 | Downgrades | Buy → Neutral |
| 05/24/2022 | 304.04% | Goldman Sachs | $3 → $2 | Maintains | Buy |
| 04/18/2022 | 1112.12% | BTIG | $10 → $6 | Maintains | Buy |
| 04/18/2022 | 1516.16% | Mizuho | $17 → $8 | Maintains | Buy |
| 01/24/2022 | 1112.12% | B. Riley Securities | $13 → $6 | Maintains | Buy |
| 01/06/2022 | 1516.16% | Goldman Sachs | $7 → $8 | Upgrades | Neutral → Buy |
| 08/03/2021 | 1314.14% | JP Morgan | $16 → $7 | Downgrades | Overweight → Neutral |
| 06/29/2021 | 3940.4% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 06/15/2021 | 3940.4% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 05/18/2021 | 4142.42% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 01/07/2021 | 3132.32% | Mizuho | → $16 | Initiates Coverage On | → Buy |
| 06/08/2020 | 2930.3% | Goldman Sachs | → $15 | Upgrades | Neutral → Buy |
| 12/06/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 12/06/2019 | 3536.36% | Goldman Sachs | → $18 | Assumes | → Neutral |
| 03/25/2019 | 3132.32% | Goldman Sachs | $17 → $16 | Downgrades | Buy → Neutral |
| 03/15/2019 | — | Raymond James | Initiates Coverage On | → Outperform | |
| 07/16/2018 | 3536.36% | Goldman Sachs | → $18 | Initiates Coverage On | → Buy |
| 07/16/2018 | 3536.36% | JP Morgan | → $18 | Initiates Coverage On | → Overweight |
| 07/16/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/16/2018 | 4344.44% | Wedbush | → $22 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年1月26日 | - | 韦德布什 | 评级下调 | 跑赢→中性 | |
| 2022年12月21日 | 506.06% | BTIG | $6→$3 | 维护 | 买 |
| 2022年08月25日 | 304.04% | 高盛 | →$2 | 评级下调 | 购买→中性 |
| 2022年05月24日 | 304.04% | 高盛 | $3→$2 | 维护 | 买 |
| 04/18/2022 | 1112.12% | BTIG | $10→$6 | 维护 | 买 |
| 04/18/2022 | 1516.16% | 瑞穗 | $17→$8 | 维护 | 买 |
| 01/24/2022 | 1112.12% | B.莱利证券 | $13→$6 | 维护 | 买 |
| 01/06/2022 | 1516.16% | 高盛 | $7→$8 | 升级 | 中性→购买 |
| 08/03/2021 | 1314.14% | 摩根大通 | $16→$7 | 评级下调 | 超重→中性 |
| 2021/06/29 | 3940.4% | 康托·菲茨杰拉德 | →$20 | 开始承保 | →超重 |
| 2021/06/15 | 3940.4% | BTIG | →$20 | 开始承保 | →购买 |
| 2021/05/18 | 4142.42% | B.莱利证券 | →$21 | 开始承保 | →购买 |
| 01/07/2021 | 3132.32% | 瑞穗 | →$16 | 开始承保 | →购买 |
| 06/08/2020 | 2930.3% | 高盛 | →$15 | 升级 | 中性→购买 |
| 2019年6月12日 | - | BTIG | 开始承保 | →购买 | |
| 2019年6月12日 | 3536.36% | 高盛 | →$18 | 假设 | →中性 |
| 2019年03月25日 | 3132.32% | 高盛 | $17→$16 | 评级下调 | 购买→中性 |
| 2019年03月15日 | - | 雷蒙德·詹姆斯 | 开始承保 | →跑赢大盘 | |
| 2018年07月16日 | 3536.36% | 高盛 | →$18 | 开始承保 | →购买 |
| 2018年07月16日 | 3536.36% | 摩根大通 | →$18 | 开始承保 | →超重 |
| 2018年07月16日 | - | 考恩公司 | 开始承保 | →跑赢大盘 | |
| 2018年07月16日 | 4344.44% | 韦德布什 | →$22 | 开始承保 | →跑赢大盘 |
What is the target price for Magenta Therapeutics (MGTA)?
品红治疗公司(MGTA)的目标价格是多少？
The latest price target for Magenta Therapeutics (NASDAQ: MGTA) was reported by Wedbush on January 26, 2023. The analyst firm set a price target for $0.00 expecting MGTA to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
韦德布什于2023年1月26日报道了品红治疗公司(纳斯达克：MGTA)的最新目标价。这家分析公司将目标价定为0.00美元，预计MGTA将在12个月内下跌(跌幅可能为-100.00%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Magenta Therapeutics (MGTA)?
洋红色治疗公司(MGTA)的最新分析师评级是多少？
The latest analyst rating for Magenta Therapeutics (NASDAQ: MGTA) was provided by Wedbush, and Magenta Therapeutics downgraded their neutral rating.
马京塔治疗公司(纳斯达克代码：MGTA)的最新分析师评级由韦德布什提供，马京塔治疗公司下调了其中性评级。
When is the next analyst rating going to be posted or updated for Magenta Therapeutics (MGTA)?
Magenta治疗公司(MGTA)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Magenta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Magenta Therapeutics was filed on January 26, 2023 so you should expect the next rating to be made available sometime around January 26, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与洋红治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Magenta治疗公司的上一次评级是在2023年1月26日提交的，所以你应该预计下一次评级将在2024年1月26日左右的某个时候提供。
Is the Analyst Rating Magenta Therapeutics (MGTA) correct?
分析师对洋红治疗公司(MGTA)的评级正确吗？
While ratings are subjective and will change, the latest Magenta Therapeutics (MGTA) rating was a downgraded with a price target of $0.00 to $0.00. The current price Magenta Therapeutics (MGTA) is trading at is $0.50, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的洋红治疗公司(MGTA)评级被下调，目标价为0.00美元至0.00美元。目前洋红色治疗公司(MGTA)的交易价格为0.50美元，超出了分析师的预测范围。